Denali Therapeutics Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Denali is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases; it reported no approved products or product-sales revenue.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $294.1 million | $52.5 million | $329.3 million | $94.6 million |
| Research and development expense | $97.5 million | $92.7 million | $226.3 million | $178.8 million |
| General and administrative expense | $26.1 million | $21.2 million | $53.3 million | $43.7 million |
| Operating income (loss) | $170.5 million | ($61.4 million) | $49.7 million | ($127.9 million) |
| Net income (loss) | $183.4 million | ($58.8 million) | $73.6 million | ($124.0 million) |
| Diluted earnings (loss) per share | $1.30 | ($0.48) | $0.52 | ($1.01) |
- Revenue and earnings quality: Q2 collaboration revenue included $293.9 million recognized when Biogen exercised its option to license Denali’s ATV:Abeta program. The reported profit therefore reflects a material, event-driven collaboration payment, not product sales or recurring operating profitability.
- Cash flow: Net cash used in operating activities was $172.0 million for the first half, versus $115.0 million used in the prior-year period. Cash, cash equivalents and restricted cash fell by $86.0 million to $133.5 million; the company also held $1.059 billion in short-term marketable securities.
- Liquidity and obligations: Current assets were $1.224 billion and current liabilities $69.4 million at June 30. Total liabilities were $118.9 million, including $55.5 million of operating lease liabilities. The balance sheet presents no borrowing or debt line item. Management said existing cash, cash equivalents and marketable securities should fund projected operations for at least 12 months after the filing date.
- Equity and deficit: Accumulated deficit was $897.4 million. Stock-based compensation expense was $54.7 million for the first half.
Material changes versus the prior comparable period
- Q2 revenue rose by $241.6 million year over year, primarily due to the Biogen ATV:Abeta license revenue. First-half revenue increased by $234.7 million, partly offset by lower Sanofi and Takeda revenue because of milestone and activity timing.
- First-half R&D expense rose 27% to $226.3 million. Drivers included a $30.0 million F-star clinical milestone obligation, increased ETV:IDS and eIF2B activity, higher personnel and facility costs, and a shift to net cost-sharing payments to Biogen as LRRK2 activities transitioned. The filing states $24.0 million of the F-star payment had been paid by June 30; the remaining $6.0 million was paid in July.
- First-half G&A expense rose 22% to $53.3 million, mainly from higher personnel, facilities and professional-services costs.
- Interest and other income increased to $12.9 million in Q2 and $23.9 million for the first half, from $2.6 million and $3.9 million, respectively, reflecting income on cash and investments.
Outlook, management commentary and risks
- Denali expects significant operating expenses and losses to continue as it advances clinical programs and its blood-brain barrier platform. Revenue is expected to fluctuate with collaboration milestones, option exercises, reimbursements and other contract activity; product revenue depends on successful development, approval and commercialization.
- Management expects to use substantial additional funding over the longer term. The company has no committed source of additional capital; future equity or debt financing may dilute shareholders or impose other restrictions.
- Clinical and manufacturing commitments totaled $80.8 million at June 30, including $41.5 million under the Lonza development and manufacturing agreement. Operating lease liabilities were $55.5 million. The new Salt Lake City lease has approximately $13.4 million of undiscounted future payments; it had not commenced for accounting purposes at quarter-end.
- Pipeline updates: DNL310 remained in Phase 2/3 development for Hunter syndrome; Denali reported a 64% average reduction in serum neurofilament light after two years in the Phase 1/2 study. DNL343 entered the Phase 2/3 HEALEY ALS Platform Trial in May. In June, Denali and Biogen planned to revise BIIB122 development to focus on a timely efficacy readout in early Parkinson’s disease.
- Subsequent developments disclosed in the report: In August, Denali and Takeda announced discontinuation of clinical development of TAK-920/DNL919 in Alzheimer’s disease, citing the totality of Phase 1 data and strategic considerations. The filing described moderate, reversible hematologic effects at the highest dose tested and a potential narrow therapeutic window. Denali and Takeda planned to assess backup molecules. Also in August, Denali said DNL126’s IND for MPS IIIA had been accepted and planned to begin recruiting in the second half of 2023.
- Key risks include clinical failure or delays, safety findings, regulatory uncertainty, dependence on collaboration partners and contract manufacturers, manufacturing scale-up, intellectual-property challenges, competition, and the need for future financing. The company reported no litigation expected by management to have a material adverse effect.
Important facts for investors to verify
- Whether the $293.9 million Biogen ATV:Abeta license recognition is understood as nonrecurring and how much future collaboration revenue is supported by remaining obligations or potential milestones.
- Operating cash burn, investment maturities and management’s assumptions behind the stated 12-month-plus funding runway.
- Progress, enrollment, safety and data timing for DNL310, DNL343, DNL593, BIIB122 and the other clinical programs, including the planned BIIB122 study changes.
- Execution and cost of the Salt Lake City manufacturing-site build-out, and the timing and funding of the $80.8 million clinical and manufacturing commitments.
- Whether increased R&D and personnel costs, collaboration cost-sharing changes and future financing needs alter the company’s development priorities or shareholder dilution risk.